EUCTR2006-006642-34-IT进行中（未招募）不适用
Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER acutely exacerbated subjects with schizofrenia - PERTAI
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject meets the DSM-IV criteria for schizophrenia; 2. Male or female, aged greater or equal than 18 years; 3. Subject must be experiencing an acute schizophrenic episode with a PANSS total score at baseline greater or equal than 70; 4. Subject must be admitted to hospital for treatment of the acute schizophrenic episode and must agree for voluntary hospitalization for at least the first 7 days of the study; 5. Subjects or their legally acceptable representatives must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study; 6. Female subjects must be postmenopausal for at least 1 year , surgically sterile, abstinent, or, if sexually active, be practicing and effective method of birth control e.g. prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization before entry and throughout the study. Female subjects of child-bearing potential must have a negative urine pregnancy test at screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. First antipsychotic treatment ever; 2. On clozapine or a long-acting injectable antipsychotic during the last 3 months; 3. Relevant history of any significant and/or unstable cardiovascular, respiratory, neurologic including seizures or significant cerebrovascular , renal, hepatic, endocrine, or immunologic diseases, including recent or present clinically relevant laboratory abnormalities as deemed by the investigator ; 4. Known clinically relevant abnormal laboratory values or ECG; 5. History or current symptoms of tardive dyskinesia; - History of neuroleptic malignant syndrome; 6. Judged to be at high risk for or presence of violence or self-harm; 7. Pregnant or breast-feeding female; 8. Have received an experimental drug or used an experimental medical device within 30 days before the planned start of treatment; 9. Subjects with a narrowing or blockage of their gastro-intestinal tract; 10. Inability to swallow the study medication whole with the aid of water subjects may not chew, divide, dissolve, or crush the study medication, as this may affect the release profile ; 11. Subjects with a current use or known history over the past 6 months of substance dependence according to DSM-IV Criteria; 12. Employees of the investigator or study center, persons with direct involvement in the proposed study or other studies under the direction of that investigator or study center, or family members of the employees or the investigator; 13. Known hypersensitivity to paliperidone ER or risperidone
研究者
相似试验
进行中（未招募）
1 期
Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia - PERTAISubjects 18 years of age or older who meet the DSM-IV criteria for schizophrenia, experiencing an acute schizophrenic episode with a PANSS total score at baseline higher or equal as 70 and admitted to hospital for treatment of the acute schizophrenic episode.MedDRA version: 9.1Level: LLTClassification code 10001065Term: Acute schizophrenia episodeMedDRA version: 9.1Level: LLTClassification code 10001064Term: Acute schizophreniaEUCTR2006-006642-34-FRJanssen-Cilag International NV, Turnhoutsweg 30, 2340 BEERSE, Belgium300
进行中（未招募）
不适用
Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects with Schizophrenia - PERTAISubjects 18 years of age or older who meet the DSM-IV criteria for schizophrenia, experiencing an acute schizophrenic episode with a PANSS total score at baseline higher or equal as 70 and admitted to hospital for treatment of the acute schizophrenic episodeMedDRA version: 9.1Level: LLTClassification code 10001065Term: Acute schizophrenia episodeMedDRA version: 9.1Level: LLTClassification code 10001064Term: Acute schizophreniaEUCTR2006-006642-34-DEJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium300
进行中（未招募）
不适用
Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects with Schizophrenia - PERTAISubjects 18 years of age or older who meet the DSM-IV criteria for schizophrenia, experiencing an acute schizophrenic episode with a PANSS total score at baseline higher or equal as 70 and admitted to hospital for treatment of the acute schizophrenic episodeMedDRA version: 9.1Level: LLTClassification code 10001065Term: Acute schizophrenia episodeMedDRA version: 9.1Level: LLTClassification code 10001064Term: Acute schizophreniaEUCTR2006-006642-34-LTJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium300
进行中（未招募）
3 期
Comparative Efficacy, Safety and Tolerability of Fixed Dose Combination of Cephalexin Extended Release (375 mg) and Clavulanate Potassium (125 mg) Tablets with Cephalexin Extended Release (375 mg) Tablets in the Treatment of Uncomplicated Skin and Soft Tissue InfectioCTRI/2015/01/005361Sun Pharmaceutical Industires Ltd180
进行中（未招募）
3 期
Fixed Dose Combination of Cephalexin Extended Release (375 mg) and Clavulanate Potassium (125 mg) Tablets in the Treatment of Upper Respiratory Tract Infections.CTRI/2015/01/005353Sun Pharmaceutical Industries limited180